These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 17376623

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64. Tuberin negatively affects BCL-2's cell survival function.
    Freilinger A, Rosner M, Hengstschläger M.
    Amino Acids; 2006 Jun; 30(4):391-6. PubMed ID: 16773241
    [Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66. Developmental expression of the tuberous sclerosis proteins tuberin and hamartin.
    Murthy V, Stemmer-Rachamimov AO, Haddad LA, Roy JE, Cutone AN, Beauchamp RL, Smith N, Louis DN, Ramesh V.
    Acta Neuropathol; 2001 Mar; 101(3):202-10. PubMed ID: 11307618
    [Abstract] [Full Text] [Related]

  • 67. Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas.
    Fackler I, DeClue JE, Rust H, Vu PA, Kutzner H, Rütten A, Kaddu S, Sander CA, Volkenandt M, Johnson MW, Vinters HV, Wienecke R.
    J Cutan Pathol; 2003 Mar; 30(3):174-7. PubMed ID: 12641776
    [Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Differences in gene expression profile among SH-SY5Y neuroblastoma subclones with different neurite outgrowth responses to nerve growth factor.
    Oe T, Sasayama T, Nagashima T, Muramoto M, Yamazaki T, Morikawa N, Okitsu O, Nishimura S, Aoki T, Katayama Y, Kita Y.
    J Neurochem; 2005 Sep; 94(5):1264-76. PubMed ID: 15992370
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. Tuberous sclerosis as an underlying basis for infantile spasm.
    Yeung RS.
    Int Rev Neurobiol; 2002 Sep; 49():315-32. PubMed ID: 12040899
    [Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
    Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D.
    Cancer Res; 2007 Oct 15; 67(20):9878-86. PubMed ID: 17942919
    [Abstract] [Full Text] [Related]

  • 74. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin.
    Hodges AK, Li S, Maynard J, Parry L, Braverman R, Cheadle JP, DeClue JE, Sampson JR.
    Hum Mol Genet; 2001 Dec 01; 10(25):2899-905. PubMed ID: 11741833
    [Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77. The role of tuberin in cellular differentiation: are B-Raf and MAPK involved?
    Karbowniczek M, Henske EP.
    Ann N Y Acad Sci; 2005 Nov 01; 1059():168-73. PubMed ID: 16382052
    [Abstract] [Full Text] [Related]

  • 78. Differences in neuritogenic response to nitric oxide in PC12 and PC12h cells.
    Yamazaki M, Chiba K, Mohri T.
    Neurosci Lett; 2006 Jan 30; 393(2-3):222-5. PubMed ID: 16239071
    [Abstract] [Full Text] [Related]

  • 79. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis.
    Aicher LD, Campbell JS, Yeung RS.
    J Biol Chem; 2001 Jun 15; 276(24):21017-21. PubMed ID: 11290735
    [Abstract] [Full Text] [Related]

  • 80. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A, Debska-Slizień A, Konopa J, Zdrojewski Z, Rutkowski B.
    Transplant Proc; 2009 Nov 15; 41(9):3677-82. PubMed ID: 19917366
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.